Aumentar fonte Diminuir fonte Imprimir Página



  • A. Ganesan - UK

    Ganesan obtained a BSc (Hons) in Chemistry at the National University of Singapore. He completed his PhD in synthetic methodology and total synthesis under the supervision of Clayton Heathcock at the Department of Chemistry, University of California-Berkeley, followed by a postdoctoral stint with Gregory Verdine at the Department of Chemistry at Harvard University. He then joined the Centre for Natural Product in Singapore and later became a Principal Investigator of the Institute of Molecular and Cell Biology.  In 1999 he moved to the Department of Chemistry at the University of Southampton in the UK. In 2011 he took up his current position as Chair of Chemical Biology at UEA’s School of Pharmacy.

    Ganesan is co-founder of the biotech company Karus Therapeutics, Chair of the EU COST Action TD1406, 'Epigenetic Chemical Biology’ and sits on the IUPAC Subcommittee for Medicinal Chemistry and Drug Development. His research interests are in medicinal chemistry and chemical biology with a focus on natural products and epigenetics. 

  • Alberto Carlos Pires Dias - Portugal

    Degree in Applied Biology), MSc in Biotechnology, PhD. He is coordinator of CITAB-UM, center FCT. He worked three years in Quatrum (Portuguese pharmaceutical company) in research quality. Professor at the University of Minho in the Dep. Of Biology, since 1991

    His research area includes the study of secondary metabolism of plants, metabolites and their bioactivities, focusing on antioxidant properties, anti-inflammatory and neuroprotective. Additionally, and more recently, they have promoted the development of products incorporating biofunctional extracts, fractions and compounds in various medicinal plants arrays (nanoparticles, textiles, cosmetics, nutraceuticals).

    It was coordinator of several FCT and European projects (EU-FP7), as well as bilateral programs Portugal-Spain and Portugal- Germany. He participated in the organization or was Chair of several Congresses and Symposia national and international, in the area of natural products and medicinal and aromatic plants. 

  • Ana Martinez - Spain

    Dr. Ana Martinez is Research Professor at the Biological Research Center (CIB) of Spanish National Council for Research (CSIC), having a background formation on Medicinal Chemistry. Her interest is focused on neurodegenerative disorders, leading numerous research projects on the medicinal chemistry and rational drug design of new drugs for Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, spinal cord trauma and multiple sclerosis. Since February 2002 till January 2008, to complete a technology transfer process, she joined to NeuroPharma, after named NOSCIRA, as R&D Director. She provided strategic, leadership management and guidance in R&D activities, reaching two of her research compounds, named NP-12 (tideglusib) and NP-61, clinical trials as disease modifying agents for Alzheimer's disease. She is author of more than a two hundred scientific publications, thirty active patents in the field and editor of several books. She acts as scientific advisory board for several SMEs in the biotech field and expert for national and international evaluation research grants. Recently, she is founder and CSO of ANKAR PHARMA, an spin-off from CSIC which goal is to fill the gap between basic drug discovery research and clinical trials for new and innovative drugsum.


  • Ben Boyd - Australia

    Professor Ben Boyd is Professor of Drug Delivery Sciences at Monash Institute of Pharmaceutical Sciences (MIPS). His group’s research focusses on colloidal and structural aspects of lipids, lipid self-assembly and pharmaceutical systems, focused on controlling materials at the colloidal scale for delivery in pharma and other fields. His group is also active in developing new synchrotron-based characterization approaches for lipid and solid state systems. He is current President of the Australian Chapter of the Controlled Release Society, and is Secretary of global CRS.

  • Ben Whalley - UK

    Professor Whalley is a preclinical neuropharmacologist who employs electrophysiological and behavioural methods with animal models of disease to study the potential therapeutic benefits of components of cannabis in central nervous system disorders. 


  • Carmen Gil - Spain

    Dr. Carmen Gil received her Ph.D. from Complutense University of Madrid in 2001 under the supervision of Prof. A. Martinez. After a postdoctoral appointment at Bonn University (Prof. Dr. Stefan Bräse), she joined the Medicinal Chemistry Institute (IQM-CSIC) in 2004 (first, as Associate Researcher and since 2007 as Staff Scientist) holding the responsibility of the design and synthesis of biologically active organic molecules in the neurodegenerative field. Her research areas have been focused on phosphodiesterase inhibitors as innovative drug candidates for neurological disorders. One of her molecules is currently in regulatory preclinical development to reach clinical trials for Parkinson’s disease. Since February 2014, she is founder of ANKAR PHARMA and since April 2014, she moves to the Biological Research Center (CIB-CSIC) for advance her drug discovery projects.

  • Christian Pellevoisin - France

    After a PhD in neuroscience and a few years of teaching, Christian Pellevoisin joined L’Oréal where he began to work in the field of alternative methods and tissue engineering. In 2011 he joined EPISKIN, a subsidiary of L’Oréal, dedicated to development and production of reconstructed human epithelia as scientific director. Since now 4 years, he is in charge of the scientific and technical support to customers and he developed, in partnership with several universities, a program of education and training of the next generation of scientist to the challenge of the XXIst century. 

  • David Newman - USA

    David Newman retired as Chief of the Natural Products Branch (NPB) in the Developmental Therapeutics Program at the National Cancer Institute in Frederick, Maryland, USA in early January 2015 having spent almost 24 years with the branch, the last 10 as Chief.  Born in the UK he received an M.Sc. in synthetic organic chemistry from the University of Liverpool and a D. Phil. in microbial chemistry from the University of Sussex. He went to the USA in1968 as a post-doctoral fellow in the Biochemistry Department at the University of Georgia, and in 1970 joined the then Smith Kline & French (now GSK) as a biological chemist working mainly on antibacterial and antifungal agents from microbes.  In 1985 he left SK&F when they closed their anti-infective program, and following work in marine and microbial discovery programs at various companies in the USA, he joined the NPB in 1991 with responsibilities for marine and microbial collection programs and development of compounds there from as potential anti-cancer leads.  Following Gordon Cragg’s retirement from the position of Chief in Jan 2005, he was acting chief until formally appointed chief of the NPB in 2006.

    His research interests are in natural product structures as leads to drug candidates and their subsequent development to drugs. Two of the leads that he worked on over the years have become approved drugs, one antibacterial (ardicin) and one antitumor (halaven), with a significant number of other compounds reaching clinical trials in man in cancer.

    He is the author or coauthor of over 175 papers, reviews and book chapters related to natural products and close chemical relatives, and holds 21 patents (UK, WIPO and USA) mainly on microbial products.

    He is both a Chartered Chemist (CChem, FRCS) and a Chartered Biologist (CBiol, FSB) in the UK and EU, and now has a small consulting business covering natural products and their utility as drug leads / drugs.

  • David Wink - USA

    Deputy Director for Translational Science: Cancer Inflammation Program, National Cancer Institute, NIH, Frederick, MD USA

    1999 - Present: Senior Investigator/Molecular Mechanism Section Chief, Radiation Biology Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD

    2006 - Present: Chair, Cancer redox Biology Faculty

    2012 - Present: Adjunct: Cancer Inflammation Program

  • Dieter Schinzer - Germany

    Since 2002 Schinzer is head of the company MOLISA (Molecular Links Saxony-Anhalt) , based in Magdeburg .From 2002 to 2005 he was dean of the Faculty of Process and Systems Engineering at the University of Magdeburg. Schinzer was and still is in numerous committees of European science organization COST active.

    Schinzer is primarily concerned with the total synthesis of biologically active natural products , with drug designand the relationship between chemical structure and function of molecules. Besides Samuel Danishefsky andKyriacos Costa Nicolaou counted Schinzer to the first, where a total synthesis of epothilone succeeded.

  • Frank Kloprogge - UK

    Recently, Dr Kloprogge has joined the Clinical Pharmacology & Therapeutic Group at University College London, where he works together with Prof Della Pasqua on translational pharmacology efforts in chronic and infectious diseases.

  • Gary Walsh - Ireland

    Gary Walsh is Chair of Industrial Biotechnology at the University of Limerick, Ireland.  His research interests span various aspects of pharmaceutical and enzyme biotechnology and his 250 publications include 10 authored books, 2 edited books, 20 book chapters and 80 journal articles.   He has served as (founding) editor, biotechnology section, of the European Journal of Pharmaceutics and Biopharmaceutics and as a member of the editorial boards of Biopharm. International, New Drugs and the Encyclopaedia of Industrial Biotechnology.  He has also served as scientific secretary and as a member of the board of governors of the European Association of Pharmaceutical Biotechnology and is a former Fulbright research visiting professor at the University of Georgia, in the United States.

  • George Drusano - USA

    Dr. George Drusano is Professor of Medicine (tenured) and Director, Institute for Therapeutic Innovation of the University of Florida. He was Section Editor for Antimicrobial Agents and Chemotherapy for 10 years. He is currently an Editor for mBio. He is the author of over 290 peer-reviewed articles. Prof. Drusano has focused his research on mathematical modeling and pharmacodynamics of anti-infective chemotherapy. He was a member of the ICAAC and IDSA Program Committees. He served as an ad hoc member of NIAID Council. He consults for NIAID and CDC on Biodefense issues. He was Chair of the Gordon Conference on New Antimicrobial Discovery and Development (2010). Prof. Drusano has won a number of awards: 1) Distinguished Investigator (2003) by the American College of Clinical Pharmacology 2) Maxwell Finland Award for Scientific Achievement (2012) from the National Foundation for Infectious Diseases 3) Cubist-ICAAC award (2013) from ASM.

  • Hamid Ghandehari - USA

    Dr. Hamid Ghandehari is a Professor at the Departments of Bioengineering and Pharmaceutics and Pharmaceutical Chemistry, Director of Utah Center for Nanomedicine and Co-Founder and Co-Director of the Nano Institute of Utah at the University of Utah. His research focuses on the design of new polymers for gene therapy of head and neck cancer, targeted delivery of polymer therapeutics to solid tumors, oral delivery of chemotherapeutics, and assessing the biocompatibility of silica and dendritic nanoconstructs. Dr. Ghandehari is Editor in Chief of Advanced Drug Delivery Reviews, Fellow of the American Institute for Medical and Biological Engineering, the American Association of Pharmaceutical Scientists and the Controlled Release Society. He has published nearly 150 articles, and given nearly 200 invited talks. He received his BS in Pharmacy and PhD in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah.

  • Harren Jhoti - UK

    Dr. Jhoti, is President & CEO of Astex Pharmaceuticals in Cambridge, England. He co-founded Astex in 1999 and successfully raised over £50m from US and European venture capitalists. In Oct 2013 Astex was acquired by Otsuka Pharmaceuticals for $886m, the 7th largest global M&A deal in 2013, and now operates as a wholly-owned subsidiary of Otsuka.

    Dr. Jhoti was this year elected a Fellow of the Academy of Medical Sciences and was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012. He was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007.

    Dr. Jhoti currently serves on the Board of the BIA, the UK BioIndustry Association and is also a member of its Executive Committee. Before founding Astex in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999).  Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989.

  • Ian Waddell - UK

    Dr Ian Waddelljoined the Drug Discovery centre at the CRUK Manchester Institute for Cancer Research in June 2011 as Head of Biology. He gained a BSc and PhD in Biochemistry at the University of Dundee focusing on hepatic carbohydrate metabolism. After a short spell in the US as a post doc he spent 5 years as a lecturer in Molecular Medicine in the Department of Child Health back in Dundee before joining Zeneca in 1994. His interest in Oncology began when he led the Cachexia team looking at preventing the skeletal muscle wasting associated with pancreatic cancer. Following the merger with Astra in 2000 he returned to Diabetes and Obesity as a project manager and was directly involved in a number of projects which have subsequently progressed to late stage clinical trials. In 2005 he moved into the Oncology group at Alderley Park as Director of Bioscience where amongst other things he led the High Throughput Screening (HTS), lead identification and lead optimisation groups (including CIPG). In his last three years at AZ Ian was the Oncology Director of Discovery Medicine at Alderley Park and was responsible for the preclinical translational science aspects of all development compounds emerging from that site.

  • James Bradner - USA

    Jay Bradner is a Physician-Scientist in the Department of Medical Oncology at the Dana-Farber Cancer Institute and an Associate Professor in the Department of Medicine at Harvard Medical School. The research focus of the Bradner laboratory concerns the chemical modulation of chromatin structure and function. The clinical objective of the Bradner group is to deliver novel cancer therapeutics for human clinical investigation.
    Dr. Bradner’s awards and honors include the Damon Runyon-Rachleff Innovation Award, the Smith Family Award for Excellence in Biomedical Research, the Dunkin Donuts Rising Star Award and the HMS Distinguished Excellence in Teaching Award. He was elected into the American Society of Clinical Investigation in 2011 and the Alpha Omega Alpha medical society in 2013. His recent research has been published in Nature, Cell, Nature Chemical Biology and the Journal of the American Chemical Society. He has authored more than thirty United States Patent applications and is a scientific founder of Acetylon Pharmaceuticals, SHAPE Pharmaceuticals, Tensha Therapeutics and Syros Pharmaceuticals. Three first-in-class molecules arising from his research are presently studied in open Phase I and Phase II clinical trials. Dr. Bradner also serves on the Board of Directors for the Leukemia & Lymphoma Society and the American Society of Hematology.
    Dr. Bradner received his AB from Harvard University, his MD from the University of Chicago, and an MMS from Harvard Medical School. He completed his postgraduate training in Internal Medicine at Brigham & Women's Hospital, followed by fellowships in Medical Oncology and Hematology at Dana-Farber Cancer Institute. Following additional post-doctoral training in Chemistry with Prof. Stuart Schreiber at Harvard University and the Broad Institute, where he now serves as the Associate Director for the Science of Therapeutics. Dr. Bradner joined the research faculty of Dana-Farber in 2008

  • Jan Tytgat - Belgium

    Full Professor and Head of Toxicology & Pharmacology of the University of Leuven (KU Leuven), Belgium

    Active and expertise in two domains: 1) analytical toxicology for forensic science, and 2) molecular pharmacology in the field of drug discovery.

    Author of more than 200 peer-reviewed papers.

  • Katrina Miranda - USA

  • Laszlo Kurti - USA

    Professor László Kürti received excellent training in the total synthesis of complex natural products during his gradaute studies at Universtity of Pennsylvania with Professor Amos B. Smith III as well as in methods development, mechanistic studies and medicinal chemistry during his postdoctoral studies at Harvard University with Nobel Laureate Professor Elias J. Corey. During his graduate studies in 2005 he co-authored the now highly popular textbook/reference book „Strategic Applications of Named Reactions in Organic Synthesis”. During the next five years he co-authored two more textbooks, „Molecules and Medicine” as well as „Enantioselective Chemical Synthesis: Methods, Logic and Practice”. All three books have been well-received in both academia and industry and are widely used worldwide.

    Professor Kürti began his independent career in 2010 at UT Southwestern Medical Center in Dallas Texas but on June 1, 2015 he moved his lab to Rice University in Houston, TX where he is now an associate professor of chemistry.

    The Kürti labhas been exploring several fundamentally new strategies and methods for the creation of novel C-C and C-heteroatom bonds that expand the toolbox of synthetic organic chemists and enable the environmentally friendly (i.e., green) construction of complex molecular structures. A highly attractive, but currently underdeveloped, approach is the utilization of weak bonds (e.g., N-N, N-O) as a driving force to achieve the rapid formation of much stronger bonds under mild conditions. During the past three years his laboratory has successfully exploited these weak bonds and developed a number of transition-metal-free direct C-C and C-N bond-forming reactions.

  • Lena Friberg - Sweden

    Dr Lena Friberg is a Professor in Pharmacometrics at Uppsala University, Uppsala, Sweden. Her research focuses on Pharmacokinetic-Pharmacodynamic modeling in oncology and bacterial infections, with a special interest of using translational aspects from preclinical to clinical and from early to late clinical drug development.

  • Marcela Carolina Jirn Aliste - Chile

    Dr. Marcela Jirón is Clinical Pharmacist, PhD,  Master of Clinical Epidemiology at University of Chile and Postdoc in Pharmacoepidemiology at the University of  North Carolina at Chapel Hill, USA. At this time, Dr. Jirón is Professor at University of Chile in clinical pharmacology, clinical pharmacy and pharmacoepidemiology for undergraduate and postgraduates programs. She also is Chair of the Pharmacoepidemiology Chapter at International Society for Pharmacoepidemiology and Risk Management, Director of Student Affairs at Facultad de Ciencias Químicas y Farmacéuticas of the Universidad de Chile, Assessor of Minister of Health in Chile and National and International Pharmaceutical Companies on Pharmacovigilance, Clinical Pharmacology and Clinical Research Methods.

  • Martin Stewart - USA

    Martin Stewart is originally from Australia but completed his PhD in Germany and Switzerland. His doctoral research focused on the topic of cell mechanics and shape in mitosis. He is currently a postdoctoral fellow in the Langer and Jensen labs at MIT working on microfluidic intracellular delivery technologies.

  • Michael Mitchel - USA

    Dr. Michael J. Mitchell is an NIH-National Cancer Institute Ruth L. Kirschstein Postdoctoral Fellow in the Department of Chemical Engineering at the David H. Koch Institute for Integrative Cancer Research at MIT, supervised by Dr. Robert Langer. He received his Ph.D. in Biomedical Engineering from Cornell University in 2014, under the supervision of Dr. Michael King. At Cornell, he developed a therapeutic approach to target and kill circulating tumor cells in the bloodstream before metastatic tumor formation, where circulating white blood cells are utilized to display the cancer-specific TNF-related apoptosis inducing ligand (TRAIL) and the E-selectin adhesion receptor. The results of this work were reported in the Proceedings of National Academy of Sciences, and gained national and international attention from over 100 different news organizations. His doctoral research was recognized internationally through awards from the Biomedical Engineering Society, International Society of Biorheology, American Institute of Chemical Engineers, and Society for Biomaterials.

    In Dr. Robert Langer’s lab at MIT, Dr. Mitchell is developing new strategies to deliver therapeutics to the bone marrow microenvironment. Specifically, he has identified polymeric nanoparticle platforms that, for the first time, enable potent gene delivery to bone marrow endothelium and hematopoietic stem cells in vivo. These platforms are currently being investigated for the prevention of breast and prostate cancer metastasis to bone, the treatment of multiple myeloma, and to increase the therapeutic efficacy of bone marrow stem cell transplantations.

  • Monika Shfer-Korting - Germany

    Full Professor of Pharmacology and Toxicology, FU Berlin

    Executive Vice-President of the Freie Universität Berlin


    Doctoral thesis, Pharmacology, Goethe-Universität Frankfurt/M (Germany


    Postdoctoral Fellow Technische Universität München

    Since 1994

    Full professor of Pharmacology at the Institut für Pharmazie, Freie Universität Berlin

    Since 2013

    Principle investigator of the Collaborative Research Centre 1112 “Nanocarriers: architecture, transport, and topical application of drugs for therapeutical use”

    Since 2014

    Speaker of the BMBF-funded research platform BB3R on alternatives to animal experiments and humane research

    Honors and Awards(e.g.)

    2008                     Dorothy Hegarty Award (ATLA)

    1983-1985          Fellowship from the Boehringer Ingelheim Fonds, Germany

  • Oscar Della Pasqua - United Kingdom

    In addition to his academic position as Chair Clinical Pharmacology & Therapeutics at the University College London, United Kingdom , Prof Della Pasqua has longstanding experience in pharmaceutical R&D at GlaxoSmithKline, where he is Senior Director Clinical Pharmacology. His track records in clinical drug development are highlighted by his contribution to more than 80 publications in international journals, book chapters and over 10 PhD theses.

    Prof Della Pasqua has been actively involved in a number of initiatives aimed at the integration of quantitative clinical pharmacology concepts into drug development and therapeutics.  This work has been performed in close partnership with the European Federation of Pharmaceutical Industry Association (EFPIA) and European Medicines Agency (EMA).

  • Peter Ford - USA


    Professor Ford has been a member of UC Santa Barbara Faculty of Chemistry his entire career, during which time he has supervised the thesis research of about 70 Ph. D. students.  He has received the 2008 Award in Photochemistry from the InterAmerican Photochemical Society, the 2013 Award for Distinguished Service to Inorganic Chemistry from the American Chemical Society and the 2015 Inorganic Mechanisms Award from the Royal Society of Chemistry.  He has long been associated with Brazil and has hosted a number of Brazilian scientists in his laboratories as visiting faculty, postdoctoral researchers or graduate students.   Professor Ford's current research interests are in the sustainable chemistry of renewable resources and in developing photochemical methodologies for releasing bioactive small molecules at physiological targets.

  • Phillipe Masson - France

  • Ricardo Kratje - Argentina

    Ricardo Kratje is currently Professor of Cell Culture Technology in the School of Biochemistry and Biological Sciences at the Universidad Nacional del Litoral and Main Researcher of the National Council of Scientific and Technical Research (CONICET) in Santa Fe City (Argentina). He graduated in Biochemistry (1980) and Pharmacy (1988) at the Universidad de Buenos Aires (Buenos Aires City, Argentina), and received in 1985 his PhD in Biochemistry from the same University for his work on the effects of Ca2+ and alkali metal ions on active Ca2+ transport in human red cells. Subsequently, he was Head of Section of Injections and Pomades at the Production Department of Schering Argentina (1986-1988).
    In 1989, Ricardo Kratje worked as a Post-doctorate at the Helmholtz-Zentrum für Infektionsforschung (called at that time Gesellschaft für Biotechnologische Forschung) in Braunschweig, Germany, where he joined the research group of Prof. Roland Wagner, working on the expertise area of high cell density cultivation of animal cells.
    In 1992, Ricardo Kratje moved to his current workplace in the School of Biochemistry and Biological Sciences at the Universidad Nacional del Litoral, where he created the Cell Culture Laboratory, and in 1996 received the Habilitation for Biotechnology at the Universidad Nacional del Litoral on the subject referred to production of recombinant proteins in animal cell culture. In addition, in 1992 he co-founded the biotechnological company Zelltek, that is currently part of the Amega Biotech Group, a business dedicated to the development and production of biosimilars. He is (co-)author of more than 40 full publications in international journals, and has supervised more than 10 Ph.D. thesis

  • Richard Minshall - USA

    Dr. Richard Minshall earned his PhD in Pharmacology from the University of Illinois at Chicago (UIC) in 1996 under the guidance of Prof. Ervin Erdös where he investigated cardioprotective mechanisms of ACE inhibitors and bradykinin actions in the heart. He then conducted Postdoctoral research on the role of steroids hormones in the regulation of coronary artery reactivity in postmenopausal monkeys at the Oregon National Primate Research Center and Oregon Health Sciences University. Rich then returned to UIC where he was awarded a Parker B. Francis fellowship in Lung Biology under Prof. Asrar B. Malik, and over the last 15 years, he has risen through the ranks - currently an Associate Professor of Pharmacology and Anesthesiology. He has published over 130 peer-reviewed manuscripts and reviews, and during his faculty tenure at UIC, Rich has been able to maintain continuous extramural NIH research funding and mentor 40 students, postdocs, and residents in translational endothelial cell pathobiology. The focus of his current research program is to understand how structural and scaffolding functions of caveolin-1 regulate formation and trafficking dynamics of caveolae, cellular signaling, adherens junction integrity, and vWF secretion. His group is also investigating the role of caveolin-1 in the regulation of cellular crosstalk involved in PMN adhesion and transmigration as well the proliferation and transdifferentiation of endothelial cells during repair and pathological vascular remodeling associated with Acute Lung Injury, Diabetes, Sickle Cell Disease, and Alzheimer’s Disease.

  • Robert Lee - USA

    Dr. Robert Lee received his Ph.D. from Purdue University in 1994.  He received postdoctoral training at University of Pittsburgh and worked at GeneMedicine and then at Endocyte prior to joining the faculty of Ohio State University College of Pharmacy in 1997.  Dr. Lee is an expert on lipid-based drug delivery systems and has published over 170 articles on drug delivery and is a recognized expert in the field of nanomedicine.

  • Sandeep Kale - India

    Dr. Sandeep B. Kale is Deputy Co-ordinator of DBT-ICT-Centre Energy Biosciences at Institute of Chemical Technology (formerly UDCT), Mumbai, India. He is a group leader of Bioprocessing, Health, Nutrition and Chemistry group at DBT-ICT-Centre Energy Biosciences at ICT Mumbai. He obtained his Bachelor of Pharmacy degree from Pune University, and Masters in Bioprocess Technology and Ph. D (Tech) in Chemical Engineering from UDCT (Mumbai University). He has 25 publication and 25 patents. He has delivered 63 presentations at national and international conference. He has received various honors and fellowships. In the year 2006, he received ‘Young Scientist Award in Biochromatography from SBCN, France, for cost effective technology in processing of bio/pharmaceuticals. He has also received Dr. PD Sethi award and Dr. R.K. Khanna Memorial award for best research papers. He is member Board of Director of “Abhay Cotex Pvt. Ltd., India. He is currently consultant to Mitsubishi Chemicals Corporation, Japan, General Mills India, and Catapro Technologies, Nashik.  His research is focused on development of new generation bioprocesses for biotech, biopharma/biologics, agricultural and natural products. He has transferred 4 technologies to the industries located in India and abroad. He has active collaboration with Curtin University, QUT and CSIRO Australia; Washington State University, USA and Aberystwyth University, UK. He is currently an investigator of projects funded by DBT, DSIR, RGSTC and Industries amounting over 25 crores.

  • Stephan Schmidt - USA

    Dr. Schmidt joined the University of Florida as an Assistant Professor at the Center for Pharmacometrics and Systems Pharmacology (CPSP) in Lake Nona (Orlando) in January 2012.

    His research focuses on the application of quantitative (pharmacometrics and systems pharmacology) tools to address clinically relevant research questions in the area of antimicrobial chemotherapy, pediatrics, diabetes, cardiovascular safety and post-menopausal osteoporosis. Dr. Schmidt published his work in more than 10 peer-reviewed journals including Clinical Pharmacology & Therapeutics, CPT: Pharmacometrics & Systems Pharmacology, the British Journal of Clinical Pharmacology, the Journal of Pharmaceutical Sciences, Clinical Pharmacokinetics, and Antimicrobial Agents and Chemotherapy. He is the editor of a book entitled, “Applied Pharmacometrics”, published in 2014 as part of an AAPS series on advancing Pharmaceutical Sciences. Dr. Schmidt received the Paul Ehrlich Society for Chemotherapy Thesis Award for his work on “Pharmacokinetics/Pharmacodynamics of oxazolidinones and beta-lactams” in 2010, the University of Florida Clinical Translational Science Institute Junior Faculty Pilot Program Award in 2012 as well as the University of Florida Excellence Award for Assistant Professors in 2013.

  • Xiaoyuan Chen - USA

    Dr. Xiaoyuan (Shawn) Chen received his PhD in Chemistry from the University of Idaho (1999). After two postdocs at Syracuse University and Washington University in St. Louis, he started his Assistant Professorship in 2002 and then moved to Stanford in 2004. He was promoted to Associate Professor in 2008. He moved to NIH in 2009 and became a Senior Investigator and lab Chief. His current research interests include the development of molecular imaging toolbox for better understanding of biology, early diagnosis of disease, monitoring therapy response, and guiding drug discovery/development. His lab puts special emphasis on high-sensitivity nanosensors for biomarker detection and theranostic nanomedicine for imaging, gene and drug delivery, and monitoring of treatment. Dr. Chen has published over 450 peer-reviewed papers (H-index = 85, total citations > 28,000) and numerous books and book chapters. He is the founding editor of journal “Theranostics” (2014 IF = 7.827). He is also the President of Chinese-American Society of Nuclear Medicine and Molecular Imaging (CASNMMI) and Vice President of the Radiopharmaceutical Science Council (RPSC), Society of Nuclear Medicine and Molecular Imaging (SNMMI).


Important Dates

  • JUN 25th
    Abstract Submission Deadline
  • AUG 05th
    Registration Deadline
  • SEP 05th
    First day




Official Bank


Executive Secretariat

2014 - 2015 © Todos os direitos reservados a CIFARP.